UltraShape Device for Thigh Fat and Circumference Reduction vs. Control

Study Overview
=================
Brief Summary
-----------------
UltraShape Device for Thigh Fat and Circumference Reduction: Prospective, blinded, one arm, baseline-controlled clinical study for the evaluation of the UltraShape treatment for non-invasive fat and circumference reduction.

Detailed Description
-----------------
UltraShape Device for Thigh Fat and Circumference Reduction- Up to 60 healthy adult volunteers seeking for noninvasive thighs circumference reduction, male and females, 18 to 60 years of age from up to four investigational sites. Eligible subjects will receive 3 bi-weekly treatments (2 weeks interval) on one randomized thigh with the UltraShape device according to the study protocol. The other thigh will not be treated during the main study phase (and serve as control). The subjects will return for 3 follow up visits: four weeks (4wk FU), eight weeks (8wk FU) and 16 weeks (16wk FU) after the last treatment. Total expected study duration: 20-22 weeks. Should the subject choose to receive additional optional treatments on the untreated side, up to three bi-weekly treatments will be performed upon study completion at no cost to the subject while changing total study duration to 24-26 weeks.

Official Title
-----------------
Clinical Study to Evaluate the Performance of the UltraShape Device for Thighs Fat and Circumference Reduction vs. Control

Conditions
-----------------
Unwanted Thigh Fat

Intervention / Treatment
-----------------
* Device: Ultrashape


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Signed informed consent to participate in the study. Female and male subjects,18 and 60 years of age at the time of enrolment Fitzpatrick Skin Type I to VI. Fat thickness of at least 1.5 cm in the treated area (measured by calibrated caliper). BMI interval: BMI in range of 22- 30 (normal to overweight, but not obese). If female, not pregnant or lactating, must be either post-menopausal, surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment (i.e., oral contraceptives, contraceptive implant, barrier methods with spermicide or abstinence). In addition, negative urine pregnancy test as tested before each treatment and at the last follow-up visit for women with child-bearing potential (e.g. not menopause). General good health confirmed by medical history and skin examination of the treated area. Willing to follow the treatment and follow-up schedule and post-treatment care instructions. Willingness to refrain from a change in diet/ exercise/medication regimen for the entire course of the study. Willing to have photographs and images taken of the treated areas to be used, de-identified in evaluations, publications and presentations. Exclusion Criteria: History of hypertension, ischemic heart disease, valvular heart disease, congestive heart failure, pacemaker/defibrillator, abdominal aortic aneurism Known hyperlipidemia, diabetes mellitus, hepatitis, liver disease, HIV positive status, blood coagulopathy or excessive bleeding, autoimmune or connective tissue disease Having or undergoing any form of treatment for active cancer, or having a history of skin cancer or any other cancer in the areas to be treated, including presence of malignant or pre-malignant pigmented lesions Having any active electrical implant anywhere in the body, such as a pacemaker or an internal defibrillator Having a permanent implant in the treated area, such as metal plates or an injected chemical substance such as silicone Having undergone any other surgery in the treated areas within 12 months of treatment or during the study, including liposuction Previous body contouring procedures in the treatment area within 12 months History of skin disease in the treatment area, known tendency to form keloids or poor wound healing Suffering from significant skin conditions in the treated areas or inflammatory skin conditions, including, but not limited to, open lacerations or abrasions and active cold sores or herpes sores prior to treatment (duration of resolution as per the Investigator's discretion) or during the treatment course Skin lesions in the treatment area other than simple nevi on physical examination (e.g., atypical nevus, tattoo, abrasions) including depressed scars in the treatment area Very poor skin quality (i.e., severe laxity) Abdominal wall diastasis or hernia on physical examination Abnormal kidney, liver or coagulation functions, abnormal lipid profile or blood count within the last 3 months Obesity (BMI bigger than 30) Childbirth within the last 12 months or breastfeeding women. Any acute or chronic condition which, in the opinion of the investigator, could interfere with the conduct of the study Unstable weight within the last 6 months (i.e tolerance of 3% weight change in the prior six months) Inability to comply with circumference measurement procedure (e.g., inability to hold breath for the required duration). Participation in another clinical study within the last 6 months. As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: all subjects treated by UltraShape<br>all the patients undergo fat reduction treatment by UltraShape | Device: Ultrashape<br>* circumference reduction<br>* Other names: fat reduction;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| evaluate the efficacy of the UltraShape device by evaluating the non-invasive fat and circumference reduction |  | 8 weeks up to 20 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| safety issues assessed by The number, severity and type of any adverse event recorded throughout the study and post treatment (immediate and delayed response) |  | day 0 up to 20 weeks | 
| thigh circumference reduction | significant thigh circumference reduction post UltraShape treatments. Reduction will be calculated at each follow-up visit (4wk FU, 8wk FU and 16wk FU) versus baseline and versus control thigh. | four weeks (4wk FU), eight weeks (8wk FU) and 16 weeks (16wk FU) after the last treatment, | 
| thigh fat thickness reduction by ultrasound | fat thickness reduction post UltraShape treatments as measured by caliper and by Ultrasound device | day 0, 2 weeks, 4 weeks, 8 weeks, 12 weeks, 20 weeks | 
| thigh fat thickness reduction by caliper | thigh fat thickness reduction | day 0, 2 weeks, 4 weeks, 8 weeks, 12 weeks, 20 weeks | 
| Subject satisfaction by questionnaire | Satisfaction assessment will be performed independently by the subject himself | 8 weeks, 12 weeks, 20 weeks | 
| Comfort level by NSR scale | Comfort level during treatment will be performed post each treatment | day 0, 2 weeks, 4 weeks | 
| Investigator satisfaction by questionnaire | assessment comparing before and after photos using the 5-Point Likert Scale | 8 weeks, 12 weeks, 20 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
non-invasive